Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01063140 · ClinicalTrials.gov registry record
Rabies Immune Plasma Booster Study
A clinical trial, sponsored by CSL Behring.
- Completed
- Registry status
- 491
- Enrollment target
NCT01063140: Completed study, sponsored by CSL Behring.
NCT01063140 is a clinical trial that has completed, run by CSL Behring. The registered enrollment target is 491 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01063140 has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- 491 participants
- Enrollment target
Study Summary
Rabies immune globulin is a product that is lifesaving to unvaccinated individuals exposed to the rabies virus. Rabies immune globulin is made from plasma from immune donors. Currently the only practical method to obtain this plasma is to immunize normal volunteer Source Plasma donors and collect their plasma while titers are adequate. The use of rabies vaccine for immunization of normal Source Plasma donors is currently limited to a level that, while protective for the individual, is unsuitable for production of rabies immune globulin. The objective of this study is to obtain efficacy and safety data regarding the rabies boostering program to demonstrate that: 1. Rabies immune plasma production can be substantially increased by giving booster doses to previously immunized donors whose titers are below 10.0 IU/mL. 2. It is safe for normal Source Plasma donors to receive booster doses of rabies vaccine on a regular basis. This study utilizes two rabies vaccines approved by the FDA, Imovax® (Sanofi-Pasteur) and RabAvert® (Novartis).
Interventions
- BIOLOGICAL Rabies Vaccine (RabAvert)
- BIOLOGICAL Rabies Vaccine (Imovax)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 491 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-05 |
What the finished NCT01063140 record still lists
NCT01063140 is an observational study that tracks outcomes without assigning an intervention. The registered 491 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Rabies Vaccine (RabAvert) is the first listed.
NCT01063140 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01063140 about?
NCT01063140 is a clinical study titled "Rabies Immune Plasma Booster Study". Rabies immune globulin is a product that is lifesaving to unvaccinated individuals exposed to the rabies virus. Rabies immune globulin is made from plasma from immune donors. Currently the only practical method to obtain this plasma is to immunize normal volunteer Source Plasma donors and collect th...
What is the current status of trial NCT01063140?
This trial is currently completed. The enrollment target is 491 participants. The study started on 2009-01. Estimated completion is 2010-05.
What interventions are being tested in trial NCT01063140?
The interventions under investigation include: Rabies Vaccine (RabAvert) (BIOLOGICAL), Rabies Vaccine (Imovax) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01063140?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03418961 · 491 participants · Phase 3
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- NCT05861973 · 492 participants · NA
SMARTer Weight Loss Management
- NCT05908331 · 492 participants · NA
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- NCT06152575 · 492 participants · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia